Shopping Cart

ERS Genomics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile

SKU
GDPH2298732D
READ MORE
USD 250
Single User License
USD 250
Site License
USD 500
Corporate User License
USD 750

ERS Genomics Ltd (ERS Genomics) offers genomic editing technologies. The company offers clustered regularly interspaced short palindromic repeats (CRISPR), a proprietary technology, which uses a complex molecule that contains protein Cas9 with one

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

ERS Genomics Ltd (ERS Genomics) offers genomic editing technologies. The company offers clustered regularly interspaced short palindromic repeats (CRISPR), a proprietary technology, which uses a complex molecule that contains protein Cas9 with one or more guide (ribonucleic acid) RNAs that binds to the genome in living cells at any preferred locations. This can be used to change the deoxyribonucleic acid (DNA) sequence at the targeted locations. It has worldwide intellectual property (IP) license for CRISPR-Cas9 that can be used for genome editing in all the living organisms. The company offers non-exclusive licenses to other companies' for internal research, research tools, kits, reagents; molecular diagnostics and others. ERS Genomics is headquartered in Dublin, Ireland.

ERS Genomics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ERS Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deal Details 9

Licensing Agreements 9

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 9

Horizon Discovery Extends Licensing Agreement with ERS Genomics 10

Knudra Transgenics Enters into Licensing Agreement with ERS Genomics 11

Bayer Enters into Licensing Agreement with ERS Genomics 11

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 12

ERS Genomics Ltd-Key Competitors 14

Key Employees 15

Locations And Subsidiaries 16

Head Office 16

Appendix 17

Methodology 17

About GlobalData 17

Contact Us 17

Disclaimer 17


List Of Figure

List of Figures

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7


List Of Table

List of Tables

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Key Facts 1

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 1

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ERS Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ERS Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 9

Horizon Discovery Extends Licensing Agreement with ERS Genomics 10

Knudra Transgenics Enters into Licensing Agreement with ERS Genomics 11

Bayer Enters into Licensing Agreement with ERS Genomics 11

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 12

ERS Genomics Ltd, Key Competitors 14

ERS Genomics Ltd, Key Employees 15

To know more information on Purchase by Section, please send a mail to

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.